Inhibitors targeting the LFA-1/ICAM-1 cell-adhesion interaction: design and mechanism of action
- PMID: 18781967
- DOI: 10.2174/138161208785740225
Inhibitors targeting the LFA-1/ICAM-1 cell-adhesion interaction: design and mechanism of action
Abstract
Leukocyte-function associated antigen-1 (LFA-1) is an alpha(L)beta(2) chain integrin expressed on the surface of endothelial cells that modulates the behavior of leukocytes by mediating their adhesion to other cells through its interaction to cell-surface ligands. The most important ligand of LFA-1 is ICAM-1 which is expressed on the surface of endothelial cells. The interaction between LFA-1 and ICAM-1 is involved in inflammatory responses and is therefore implicated in inflammatory pathologies and autoimmune diseases; and, in addition, it is involved in many cancer processes. In light of this, there is great interest in developing small molecule, orally available, inhibitors of the LFA-1/ICAM-1 interaction. A structurally diverse collection of small molecule inhibitors has been characterized and developed either to bind the IDAS site of the alpha(L) I-domain or to the MIDAS of the beta2 I-like domain. In this review, a summary of the structure and regulation of LFA-1 will be given, followed by a description of the different classes of inhibitors that have been described to date.
Similar articles
-
Cellular activation of leukocyte function-associated antigen-1 and its affinity are regulated at the I domain allosteric site.J Immunol. 2001 Aug 1;167(3):1431-9. doi: 10.4049/jimmunol.167.3.1431. J Immunol. 2001. PMID: 11466362
-
The I domain of integrin leukocyte function-associated antigen-1 is involved in a conformational change leading to high affinity binding to ligand intercellular adhesion molecule 1 (ICAM-1).J Biol Chem. 1998 Oct 16;273(42):27396-403. doi: 10.1074/jbc.273.42.27396. J Biol Chem. 1998. PMID: 9765268
-
The second domain of intercellular adhesion molecule-1 (ICAM-1) maintains the structural integrity of the leucocyte function-associated antigen-1 (LFA-1) ligand-binding site in the first domain.Biochem J. 2000 Oct 1;351(Pt 1):79-86. doi: 10.1042/0264-6021:3510079. Biochem J. 2000. PMID: 10998349 Free PMC article.
-
Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors.Peptides. 2003 Mar;24(3):487-501. doi: 10.1016/s0196-9781(03)00083-4. Peptides. 2003. PMID: 12732350 Review.
-
Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases.Med Res Rev. 2002 Mar;22(2):146-67. doi: 10.1002/med.10001. Med Res Rev. 2002. PMID: 11857637 Review.
Cited by
-
Nephroblastoma overexpressed gene (NOV) enhances RCC cell motility through upregulation of ICAM-1 and COX-2 expression via Akt pathway.Int J Clin Exp Pathol. 2015 Feb 1;8(2):1302-11. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 25973014 Free PMC article.
-
[Perioperative Venous Thromboembolism (VTE) Prophylaxis in Thoracic Cancer Patients: Chinese Experts Consensus - Interpretation of Perioperative Hypercoagulable State].Zhongguo Fei Ai Za Zhi. 2019 Dec 20;22(12):752-756. doi: 10.3779/j.issn.1009-3419.2019.12.03. Zhongguo Fei Ai Za Zhi. 2019. PMID: 31874669 Free PMC article. Chinese.
-
Fuzapladib in a randomized controlled multicenter masked study in dogs with presumptive acute onset pancreatitis.J Vet Intern Med. 2023 Nov-Dec;37(6):2084-2092. doi: 10.1111/jvim.16897. Epub 2023 Oct 9. J Vet Intern Med. 2023. PMID: 37811705 Free PMC article.
-
Naturally occurring cell adhesion inhibitors.J Nat Med. 2018 Sep;72(4):817-835. doi: 10.1007/s11418-018-1220-z. Epub 2018 May 19. J Nat Med. 2018. PMID: 29779172 Free PMC article. Review.
-
Targeting Endothelial Cell-Specific Molecule 1 Protein in Cancer: A Promising Therapeutic Approach.Front Oncol. 2021 May 24;11:687120. doi: 10.3389/fonc.2021.687120. eCollection 2021. Front Oncol. 2021. PMID: 34109132 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous